Candidates for peptide receptor radiotherapy today and in the future.
暂无分享,去创建一个
[1] E. P. Krenning,et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients , 1993, European Journal of Nuclear Medicine.
[2] O. Gratzl,et al. Locoregional Regulatory Peptide Receptor Targeting with the Diffusible Somatostatin Analogue 90 Y-Labeled , 1999 .
[3] F. Orsi,et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide , 2001, European Journal of Nuclear Medicine.
[4] C. Waldherr,et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] E. P. Krenning,et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[6] M. Langer,et al. 99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents. , 2001, Bioconjugate chemistry.
[7] R. Valkema,et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. , 2002, Seminars in nuclear medicine.
[8] M. Schwaiger,et al. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. , 2002, Bioconjugate chemistry.
[9] J C Reubi,et al. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. , 2000, Cancer research.
[10] A. Eberle,et al. Receptor targeting for tumor localisation and therapy with radiopeptides. , 2000, Current medicinal chemistry.
[11] J. Laissue,et al. Substance‐P receptors in human primary neoplasms: Tumoral and vascular localization , 1995, International journal of cancer.
[12] J. Reubi,et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.
[13] C. N. Coleman,et al. Molecular targets for radiation therapy: bringing preclinical data into clinical trials. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] E P Krenning,et al. Peptide receptor imaging and therapy. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] J. Foekens,et al. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to egf receptors , 1990, International journal of cancer.
[16] J C Reubi,et al. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. , 1997, Cancer research.
[17] W. Vale,et al. Expression of CRF1 and CRF2 receptors in human cancers. , 2003, The Journal of clinical endocrinology and metabolism.
[18] M. Schwaiger,et al. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics , 2001, European Journal of Nuclear Medicine and Molecular Imaging.
[19] J C Reubi,et al. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. , 1999, The American journal of pathology.
[20] M. Béhé,et al. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. , 2002, Seminars in nuclear medicine.
[21] J C Reubi,et al. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. , 2001, Cancer research.
[22] J. Reubi. Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.
[23] T. Visser,et al. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] J C Reubi,et al. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma , 1998, Gut.
[25] G. Slegers,et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study , 2000, European Journal of Nuclear Medicine.
[26] E. Krenning,et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma , 2000, European Journal of Nuclear Medicine.
[27] Hariprasad Gali,et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] J. Reubi,et al. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. , 2002, European journal of pharmacology.
[29] O. Gratzl,et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[30] G. D. Vincentis,et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[31] O. Gratzl,et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] W. Scheithauer,et al. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. , 1996, Nuclear medicine and biology.
[33] J. Reubi,et al. Neuropeptide Y receptor expression in human primary ovarian neoplasms , 2004, Laboratory Investigation.
[34] Franz Buchegger,et al. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] B. Bernard,et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[36] J C Reubi,et al. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. , 1999, Cancer research.
[37] J. Reubi,et al. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[38] B. Wiedenmann,et al. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours , 2000, European Journal of Nuclear Medicine.
[39] M. Rehling,et al. Somatostatin Receptor Scintigraphy , 1999 .
[40] G. Loudos,et al. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[41] L. Mazzucchelli,et al. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.